公开(公告)号：EP2644588A3

公开(公告)日：2013-12-25

申请号：EP13173408.9

申请日：2007-05-24

申请人： Phenomenome Discoveries Inc.

发明人： Cook, Lisa ,  Goodenowe, Dayan

IPC分类号： C07C59/62 ,  C07C235/08 ,  C07C59/105 ,  C07D311/72 ,  C07F9/09 ,  C07F9/10 ,  G01N33/483 ,  G01N33/487 ,  G01N33/50

CPC分类号： C07F9/103 ,  C07C59/46 ,  C07C59/62 ,  C07C235/08 ,  C07C2601/16 ,  C07D311/72 ,  C07F9/106 ,  G01N33/53 ,  G01N33/564 ,  G01N33/6848 ,  G01N33/6893 ,  G01N33/72 ,  G01N2800/28 ,  G01N2800/285 ,  G01N2800/56

摘要： The present invention describes methods for the diagnosis and differential diagnosis of the different forms of multiple sclerosis. The methods measure the intensities of specific small molecules called metabolites in samples from patients with clinically diagnosed relapsing-remitting or primary-progressive forms of multiple sclerosis and compare these intensities to the intensities observed in a population of healthy individuals, thus identifying markers of multiple sclerosis. A method is also provided for the differential diagnosis of subjects afflicted with relapsing-remitting multiple sclerosis from secondary-progressive multiple sclerosis.

摘要翻译： 本发明描述了用于多发性硬化症的不同形式的诊断和鉴别诊断的方法。 该方法测量了具有临床诊断为复发或复发性多发性硬化症的患者的样本中特异性小分子称为代谢物的强度，并将这些强度与健康个体群体观察到的强度进行比较，从而鉴定出多发性硬化症 。 还提供了用于对来自继发性进行性多发性硬化症的复发性多发性硬化症患者的鉴别诊断的方法。

公开(公告)号：EP2620147A2

公开(公告)日：2013-07-31

申请号：EP13160192.4

申请日：2007-08-27

申请人： Phenomenome Discoveries Inc.

发明人： Goodenowe, Dayan

IPC分类号： A61K31/232 ,  A61K31/661 ,  A61K31/6615 ,  A61P3/06 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00 ,  G01N33/68

摘要： The present invention relates to a compound for use in lowering cholesterol, wherein the compound is selected from the group consisting of: DHAP; 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-G3P; 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl, 2-acyl-GPE; I-alkyl, diacyl glycerol wherein sn-1=16:0, sn-2=DHA, sn-3=DHA, the sn-1 position has an alkyl ether bond, and the sn-2 and sn-3 positions have acyl bonds; 1-alkyl diacyl glycerol wherein sn-1=16:0, sn-2=18:1, sn-3=18:1, the sn-1 position has an alkyl ether bond, and the sn-2 and sn-3 positions have acyl bonds; triacyl glycerol wherein sn-1=16:0, sn-2=DHA, sn-3=DHA, and the sn-1, sn-2 and sn-3 positions have acyl bonds; and triacyl glycerol wherein sn-1=16:0, sn-2=18:1, sn-3=18:1, and the sn-1, sn-2 and sn-3 positions have acyl bonds; and pharmaceutically acceptable salts thereof.

摘要翻译： 本发明涉及用于降低胆固醇的化合物，其中所述化合物选自：DHAP; 1-酰基DHAP; 1-烷基DHAP; 1-烷基G3P; 1-烷基，2-酰基-G3P; 1-烷基，2-酰基 - 甘油; 1-烷基，2-酰基-GPE; 1-烷基，二酰基甘油，其中sn-1 = 16：0，sn-2 = DHA，sn-3 = DHA，sn-1位具有烷基醚键，并且sn-2和sn-3位具有酰基 债券; 1-烷基二酰基甘油，其中sn-1 = 16：0，sn-2 = 18：1，sn-3 = 18：1，sn-1位置具有烷基醚键，sn-2和sn-3 位置具有酰基键; 其中sn-1 = 16：0，sn-2 = DHA，sn-3 = DHA，并且sn-1，sn-2和sn-3位具有酰基键的三酰基甘油; 以及其中sn-1 = 16：0，sn-2 = 18：1，sn-3 = 18：1，并且sn-1，sn-2和sn-3位具有酰基键的三酰基甘油; 及其药学上可接受的盐。

公开(公告)号：EP2851369A3

公开(公告)日：2015-06-17

申请号：EP14187832.2

申请日：2007-02-28

申请人： Phenomenome Discoveries Inc.

发明人： Cook, Lisa ,  Goodenowe, Dayan

IPC分类号： C07F9/09 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00 ,  G01N33/68

CPC分类号： G06F19/34 ,  C07F9/10 ,  C07F9/106 ,  G01N30/7233 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/163333

摘要： The present invention is directed to a method for diagnosing a patient's non-Alzheimer's disease dementia or the risk of non-Alzheimer's disease dementia in a patient. The method comprises analyzing a blood sample from a patient by high resolution mass spectrometry to obtain accurate mass intensity data; b) comparing the accurate mass intensity data to corresponding data obtained for one or more than one reference sample to identify an increase or decrease in accurate mass intensity; and c) using said increase or decrease in accurate mass intensity to diagnose said patient's non-Alzheimer's disease dementia or the risk of non-Alzheimer's disease dementia in said patient.

摘要翻译： 本发明涉及诊断患者的非阿尔茨海默病痴呆或患有非阿尔茨海默病痴呆的风险的方法。 该方法包括通过高分辨率质谱分析来自患者的血液样本以获得精确的质量强度数据; b）将准确质量强度数据与针对一个或多于一个参考样品获得的对应数据进行比较以鉴定精确质量强度的增加或减少; 和c）使用所述精确质量强度的增加或减少来诊断所述患者的所述患者的非阿尔茨海默氏病痴呆或所述非阿尔茨海默氏病痴呆的风险。

公开(公告)号：EP2644588A2

公开(公告)日：2013-10-02

申请号：EP13173408.9

申请日：2007-05-24

申请人： Phenomenome Discoveries Inc.

发明人： Cook, Lisa ,  Goodenowe, Dayan

IPC分类号： C07C59/62 ,  C07C235/08 ,  C07C59/105 ,  C07D311/72 ,  C07F9/09 ,  C07F9/10 ,  G01N33/483 ,  G01N33/487 ,  G01N33/50

CPC分类号： C07F9/103 ,  C07C59/46 ,  C07C59/62 ,  C07C235/08 ,  C07C2601/16 ,  C07D311/72 ,  C07F9/106 ,  G01N33/53 ,  G01N33/564 ,  G01N33/6848 ,  G01N33/6893 ,  G01N33/72 ,  G01N2800/28 ,  G01N2800/285 ,  G01N2800/56

摘要： The present invention describes methods for the diagnosis and differential diagnosis of the different forms of multiple sclerosis. The methods measure the intensities of specific small molecules called metabolites in samples from patients with clinically diagnosed relapsing-remitting or primary-progressive forms of multiple sclerosis and compare these intensities to the intensities observed in a population of healthy individuals, thus identifying markers of multiple sclerosis. A method is also provided for the differential diagnosis of subjects afflicted with relapsing-remitting multiple sclerosis from secondary-progressive multiple sclerosis.

摘要翻译： 本发明描述了用于不同形式的多发性硬化症的诊断和鉴别诊断的方法。 这些方法测量来自临床诊断为复发 - 缓解型或原发进展型多发性硬化症患者的样品中称为代谢物的特定小分子的强度，并将这些强度与健康个体中观察到的强度进行比较，从而鉴定多发性硬化症的标志物 。 还提供了用于鉴别复发 - 缓解型多发性硬化症与继发性进行性多发性硬化症的受试者的鉴别诊断的方法。

公开(公告)号：EP2322531A2

公开(公告)日：2011-05-18

申请号：EP10195818.9

申请日：2007-02-28

申请人： Phenomenome Discoveries Inc.

发明人： Cook, Lisa ,  Goodenowe, Dayan

IPC分类号： C07F9/09 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00 ,  G01N33/68

CPC分类号： G06F19/34 ,  C07F9/10 ,  C07F9/106 ,  G01N30/7233 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/163333

摘要： The present invention is directed to a method for diagnosing a patient's Alzheimer's disease health state or change in health state, or for diagnosing Alzheimer's disease, dementia, cognitive impairment, the risk of Alzheimer's disease, the risk of Cognitive impairment, or the risk of dementia in a patient. The method comprises analyzing a blood sample from a patient by high resolution mass spectrometry to obtain accurate mass intensity data; b) comparing the accurate mass intensity data to corresponding data obtained for one or more than one reference sample to identify an increase or decrease in accurate mass intensity; and c) using said increase or decrease in accurate mass intensity to diagnose said patient's Alzheimer's disease health state or change in health state, or for diagnosing Alzheimer's disease, dementia, cognitive impairment, the risk of Alzheimer's disease, the risk of cognitive impairment, or the risk of dementia in said patient.

摘要翻译： 本发明涉及一种用于诊断患者的阿尔茨海默病健康状况或健康状态变化，或用于诊断阿尔茨海默病，痴呆，认知障碍，阿尔茨海默病风险，认知障碍风险或痴呆风险的方法 在病人身上 该方法包括通过高分辨率质谱分析来自患者的血液样品以获得准确的质量强度数据; b）将准确的质量强度数据与一个或多于一个参考样品获得的相应数据进行比较，以确定精确质量强度的增加或减少; 和c）使用所述精确质量强度的增加或减少来诊断所述患者的阿尔茨海默病健康状况或健康状态的改变，或用于诊断阿尔茨海默病，痴呆，认知障碍，阿尔茨海默氏病的风险，认知障碍的风险，或 所述患者的痴呆风险。

公开(公告)号：EP2851369A2

公开(公告)日：2015-03-25

申请号：EP14187832.2

申请日：2007-02-28

申请人： Phenomenome Discoveries Inc.

发明人： Cook, Lisa ,  Goodenowe, Dayan

IPC分类号： C07F9/09 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00 ,  G01N33/68

CPC分类号： G06F19/34 ,  C07F9/10 ,  C07F9/106 ,  G01N30/7233 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/163333

摘要： The present invention is directed to a method for diagnosing a patient's non-Alzheimer's disease dementia or the risk of non-Alzheimer's disease dementia in a patient. The method comprises analyzing a blood sample from a patient by high resolution mass spectrometry to obtain accurate mass intensity data; b) comparing the accurate mass intensity data to corresponding data obtained for one or more than one reference sample to identify an increase or decrease in accurate mass intensity; and c) using said increase or decrease in accurate mass intensity to diagnose said patient's non-Alzheimer's disease dementia or the risk of non-Alzheimer's disease dementia in said patient.

摘要翻译： 本发明涉及用于诊断患者的非阿尔茨海默氏病痴呆或患者中非阿尔茨海默病痴呆风险的方法。 该方法包括通过高分辨率质谱分析来自患者的血液样品以获得准确的质量强度数据; b）将准确的质量强度数据与一个或多于一个参考样品获得的相应数据进行比较，以确定精确质量强度的增加或减少; 以及c）使用所述精确质量强度的增加或减少来诊断所述患者的非阿尔茨海默氏病痴呆或所述患者中的非阿尔茨海默病痴呆的风险。

公开(公告)号：EP2620147A3

公开(公告)日：2013-10-02

申请号：EP13160192.4

申请日：2007-08-27

申请人： Phenomenome Discoveries Inc.

发明人： Goodenowe, Dayan

IPC分类号： A61K31/232 ,  A61K31/661 ,  A61K31/6615 ,  A61P3/06 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00 ,  G01N33/68

摘要： The present invention relates to a compound for use in lowering cholesterol, wherein the compound is selected from the group consisting of: DHAP; 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-G3P; 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl, 2-acyl-GPE; I-alkyl, diacyl glycerol wherein sn-1=16:0, sn-2=DHA, sn-3=DHA, the sn-1 position has an alkyl ether bond, and the sn-2 and sn-3 positions have acyl bonds; 1-alkyl diacyl glycerol wherein sn-1=16:0, sn-2=18:1, sn-3=18:1, the sn-1 position has an alkyl ether bond, and the sn-2 and sn-3 positions have acyl bonds; triacyl glycerol wherein sn-1=16:0, sn-2=DHA, sn-3=DHA, and the sn-1, sn-2 and sn-3 positions have acyl bonds; and triacyl glycerol wherein sn-1=16:0, sn-2=18:1, sn-3=18:1, and the sn-1, sn-2 and sn-3 positions have acyl bonds; and pharmaceutically acceptable salts thereof.

公开(公告)号：EP2322531A3

公开(公告)日：2011-09-07

申请号：EP10195818.9

申请日：2007-02-28

申请人： Phenomenome Discoveries Inc.

发明人： Cook, Lisa ,  Goodenowe, Dayan

IPC分类号： C07F9/09 ,  G01N27/00 ,  G01N33/483 ,  G01N37/00 ,  G01N33/68

CPC分类号： G06F19/34 ,  C07F9/10 ,  C07F9/106 ,  G01N30/7233 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/163333

摘要： The present invention is directed to a method for diagnosing a patient's Alzheimer's disease health state or change in health state, or for diagnosing Alzheimer's disease, dementia, cognitive impairment, the risk of Alzheimer's disease, the risk of Cognitive impairment, or the risk of dementia in a patient. The method comprises analyzing a blood sample from a patient by high resolution mass spectrometry to obtain accurate mass intensity data; b) comparing the accurate mass intensity data to corresponding data obtained for one or more than one reference sample to identify an increase or decrease in accurate mass intensity; and c) using said increase or decrease in accurate mass intensity to diagnose said patient's Alzheimer's disease health state or change in health state, or for diagnosing Alzheimer's disease, dementia, cognitive impairment, the risk of Alzheimer's disease, the risk of cognitive impairment, or the risk of dementia in said patient.

摘要翻译： 本发明涉及诊断患者的阿尔茨海默氏病健康状态或健康状态改变或诊断阿尔茨海默氏病，痴呆，认知障碍，阿尔茨海默病风险，认知障碍风险或痴呆风险的方法 在病人中。 该方法包括通过高分辨率质谱分析来自患者的血液样本以获得精确的质量强度数据; b）将准确质量强度数据与针对一个或多于一个参考样品获得的对应数据进行比较以鉴定精确质量强度的增加或减少; 和c）使用所述精确质量强度的增加或减少来诊断所述患者的阿尔茨海默氏病健康状态或健康状态的改变，或用于诊断阿尔茨海默氏病，痴呆，认知障碍，阿尔茨海默氏病的风险，认知障碍的风险或 所述患者中的痴呆风险。